Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Histologic and biochemical studies were carried out to compare the protective activity of various bisdiketopiperazines against the cardiac and renal toxicity induced by doxorubicin in spontaneously hypertensive rats (SHR), a well-established animal model of this disorder, with: (1) the rates of hydrolysis of these agents to form the iron-chelating derivatives (which are considered to cause a decrease in the formation of reactive oxygen intermediates) and (2) the ability of these derivatives to bind iron. SHR were given 12 weekly injections of doxorubicin, 1 mg/kg i.v. either alone or 30 min after the administration of ICRF-154, ICRF-187, ICRF-192, ICRF-197, ICRF-198, ICRF-239 and ADR-559. Semiquantitative grading of the severity of the resulting cardiac and renal lesions showed that ICRF-187, ICRF-154 and ADR-559 were the most protective, whereas ICRF-197 and ICRF-239 provided intermediate degrees of protection, and ICRF-192 and ICRF-198 were not protective. Quantitative measurements in vitro revealed only relatively small differences in the rates of opening of the two diketopiperazine rings of the various agents to form the corresponding iron-chelating diacid diamide derivatives, and in the ability of these various derivatives to remove iron from the iron-doxorubicin complex. Such differences showed no relationship with cardioprotective activity. Some bisdiketopiperazines (including ICRF-154 and ICRF-187) with cardioprotective activity also are inhibitors of DNA topoisomerase II; however, the significance of this relationship remains uncertain, since ADR-925, the open-ring derivative of ICRF-187, does not inhibit DNA topoisomerase II.
Herman
E H
EH
Division of Research and Testing (HFD-910), Food and Drug Administration, Laurel, MD 20708, USA.
Zhang
J
J
Hasinoff
B B
BB
Chadwick
D P
DP
Clark
J R
JR
Ferrans
V J
VJ
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D002317:Cardiovascular Agents / Q000494:pharmacology*; D002614:Chelating Agents / Q000494:pharmacology; D004250:DNA Topoisomerases, Type II; D054659:Diketopiperazines; D004317:Doxorubicin / Q000009:adverse effects*; D005029:Ethylenediamines / Q000494:pharmacology; D005998:Glycine / Q000031:analogs & derivatives / Q000494:pharmacology; D006321:Heart / Q000187:drug effects*; D006868:Hydrolysis / Q000187:drug effects; D007501:Iron / Q000378:metabolism*; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D011918:Rats, Inbred SHR; D011929:Razoxane / Q000031:analogs & derivatives / Q000494:pharmacology*
C107730:ADR 559; D000903:Antibiotics, Antineoplastic; D002317:Cardiovascular Agents; D002614:Chelating Agents; D054659:Diketopiperazines; D005029:Ethylenediamines; D010879:Piperazines; C070899:4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione; C036415:ICRF 192; D011929:Razoxane; C059866:ICRF 198; D004317:Doxorubicin; D007501:Iron; D004250:DNA Topoisomerases, Type II; C000283:1,2-bis(3,5-dioxopiperazin-1-yl)ethane; D005998:Glycine; C107731:4,4'-(1-methyl-1,2-ethanediyl)bis(1-methyl-2,6-piperazinedione)